NCT03738553View on ClinicalTrials.gov

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

Active, not recruitingOBSERVATIONAL
Enrollment

13

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2025

Conditions
HER2-positive Breast Cancer
Interventions
DEVICE

MRI

Diffusion Weighted Imaging and Dynamic Contrast enhanced MRI

DRUG

Trastuzumab

Single dose of Trastuzumab prior to surgery

Trial Locations (1)

98109

Seattle Cancer Care Alliance, Seattle

All Listed Sponsors
lead

University of Washington

OTHER